Panel, Conference Presentation
The Global Landscape and Opportunities for Medical Breakthroughs | Global Conference 2025
Milken InstituteUsha Lee McFarling, Jay Bradner, Doug Drysdale, Neil Kumar, Alice Pomponio, Grant Verstandig
- BridgeBio intends to target small patient populations by limiting development expenses to under $10 million per drug, aiming to complete IND submissions in approximately three years with an average spend of $6 million.
- Amgen projects the potential to reduce drug development timelines by two years using its AI system, Atomic, to expedite clinical trial site selection.
- Zephyr AI plans to utilize population health data from up to 86 million patients to automate non-clinical tasks and expand capabilities from target generation to patient identification.
- Saiban expects to convince markets and regulators of its novel depression therapy following Phase III results where 75% of patients achieved remission after two doses.
- Saiban plans to partner with real estate investors, lenders, and specialty pharmacies to build infrastructure capable of accommodating therapies requiring four to six-hour clinical sessions.
- Amgen aims to eliminate a second heart attack or prevent a first one by developing a medicine that targets the liver to shut down the gene producing LP(a).
- A medicine emulating reduced GIPR activity to address obesity is currently undergoing Phase III clinical investigation.
- Research indicates that patients with reduced GAD34 gene activity have a 53% lower likelihood of developing breast cancer, prompting a need for prevention-focused therapeutics.
- The American Cancer Society's Bright Edge investment arm maintains a portfolio split of approximately 50% therapeutics, 25% diagnostic devices, and 25% technology.
- The American Cancer Society plans to launch a third accelerator focused on digital health and social determinants, addressing financial security, food stability, and social isolation.
- BridgeBio aims to solve issues in pediatric drug development by employing regulatory innovation to bypass standard non-human primate studies that could endanger children.
- Public sector funding for fundamental research is considered vital to bridge the gap in understanding root causes for diseases like Alzheimer's, with impacts on the pipeline potentially visible 10 years out.
- BridgeBio and Amgen anticipate that global genetic databases in regions including Saudi Arabia, Pakistan, Africa, the UK, and Iceland will provide opportunities to capture new mutation signals.
- Amgen plans to partner with governments in the Middle East and the Caribbean to ensure drug accessibility through free provision or paid regulatory processes.
- Amgen intends to install a Freya supercomputer from NVIDIA at an Icelandic site to enhance pattern recognition between genetics and backgrounds.
- AI is expected to enable the creation of 100 billion agentic trial versions to identify the 20,000 most biologically interesting patient interrogations.
- The industry faces a risk that withdrawing US federal funding could cause a loss of competitive edge against nations like China while other nations continue to innovate.
- Every dollar of NIH funding for cancer research is estimated to generate roughly $2.56 in value or ROI.
- Zephyr aims to create digital or composite biomarkers that match multi-omic data to determine the right drug for the right patient at the right time.
- The average US hospital generates roughly one petabyte of data annually, yet less than 5% of this data is currently utilized in patient and physician care.
- Widespread adoption of modified psychedelic compounds requires a paradigm shift in mindset regarding safety and efficacy to overcome current skepticism.
- Opportunities exist to empower tumor registrars and care navigators with agentic AI to revolutionize diagnosis and treatment access.
- BridgeBio seeks to limit administrative delays by ensuring rate-limiting steps in drug discovery are biological or physical in nature.
- There is a perceived risk of a shortage of psychiatrists and therapists, with only 18% currently open to new patients and wait times ranging from 40 to 70 days.
- 80% of cancer patients dip into lifetime savings, and 40% go bankrupt, driving a need for financial navigation platforms like TaylorMed.
- Amgen is expanding therapeutic modalities to target "undruggable" proteins, citing the development of the first KRAS drug as a paradigm shift.
- Amgen and others aim to correlate patient genotypes with healthy individuals to identify rare or common disease insights and enrichment strategies.
- The revolution in large molecule therapeutics, particularly RNA, is expected to be accelerated by AI and multi-omic data integration.
- AI is viewed as having a more significant role in innovative medicines compared to biosimilars, though it remains important for quality measures and optimization.
- The average hospital in the United States produces roughly a petabyte of data annually, yet less than 5% of that data is currently used in patient and physician care.